| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 630201 | 10 µg | $125 | ||
| 630202 | 100 µg | $550 |
| Application | Bioassay |
|---|---|
| Format | Lyophilized from sterile PBS, pH 7.4. |
| Expression Host | E.coli |
| Target Name | IL-18, IL18, IL1F4, Interferon-gamma-inducing factor, IGIF, IL-1g |
| Species | Human |
| accession number | NP_001553.1 |
| Sources | A DNA sequence encoding the human IL18 (NP_001553.1) (Tyr37-Asp193) was expressed. |
| Molecular Weight | The recombinant human IL18 consists 157 amino acids and predicts a molecular mass of 18.2 kDa. |
| Affinity Tag | None |
| Purity | > 95 % as determined by SDS-PAGE. > 95 % as determined by SEC-HPLC. |
| Regulatory Status | RUO |
| Endotoxin level | <0.01EU per μg protein |
| Protein Concentration | Lyophilized |
| Storage and Handling | Proteins are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
Human interleukin-18 (IL-18) is a proinflammatory cytokine belonging to the IL-1 family, with a key role in innate and adaptive immunity. It is produced by macrophages, dendritic cells, epithelial cells, and other tissues as an inactive precursor that requires cleavage by caspase-1 within the inflammasome to become biologically active. IL-18 is best known for its ability to induce interferon-gamma (IFN-γ) production from natural killer (NK) cells and T cells, especially in synergy with IL-12, thereby promoting T helper 1 (Th1) immune responses.
Structurally, IL-18 is a single-chain polypeptide that adopts a β-trefoil fold typical of IL-1 family cytokines. Its primary receptor is a heterodimer composed of IL-18Rα (binding chain) and IL-18Rβ (accessory chain), which together initiate downstream signaling through the MyD88-dependent pathway and activation of NF-κB and MAP kinases. A natural high-affinity antagonist, IL-18 binding protein (IL-18BP), tightly regulates IL-18 activity by preventing receptor engagement.
Dysregulated IL-18 expression is implicated in inflammatory and autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, as well as in metabolic and cardiovascular disorders. Elevated IL-18 levels are also associated with severe infections and cytokine storm syndromes. Therapeutically, targeting IL-18 signaling—particularly through recombinant IL-18BP or neutralizing antibodies—has emerged as a strategy to control excessive inflammation. Conversely, IL-18 is being explored as an immune activator in cancer immunotherapy to enhance anti-tumor responses.
Recombinant Human IL-18 Protein TDS
Have a product or application question? Consult our FAQs or contact us.
